Septerna (SEPN) Competitors $16.89 -0.09 (-0.53%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends SEPN vs. ACAD, VCEL, XENE, MLTX, MOR, DNLI, MRUS, ZLAB, SWTX, and BHCShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Denali Therapeutics (DNLI), Merus (MRUS), Zai Lab (ZLAB), SpringWorks Therapeutics (SWTX), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Septerna vs. ACADIA Pharmaceuticals Vericel Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys Denali Therapeutics Merus Zai Lab SpringWorks Therapeutics Bausch Health Companies Septerna (NASDAQ:SEPN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends. Does the MarketBeat Community favor SEPN or ACAD? ACADIA Pharmaceuticals received 889 more outperform votes than Septerna when rated by MarketBeat users. However, 100.00% of users gave Septerna an outperform vote while only 73.14% of users gave ACADIA Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes4100.00% Underperform VotesNo VotesACADIA PharmaceuticalsOutperform Votes89373.14% Underperform Votes32826.86% Which has preferable earnings and valuation, SEPN or ACAD? Septerna has higher earnings, but lower revenue than ACADIA Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepternaN/AN/AN/AN/AN/AACADIA Pharmaceuticals$726.44M4.02-$61.29M$0.7822.53 Does the media favor SEPN or ACAD? In the previous week, ACADIA Pharmaceuticals had 12 more articles in the media than Septerna. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 0 mentions for Septerna. ACADIA Pharmaceuticals' average media sentiment score of 0.56 beat Septerna's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Septerna Neutral ACADIA Pharmaceuticals Positive Do analysts recommend SEPN or ACAD? Septerna presently has a consensus target price of $43.67, suggesting a potential upside of 158.54%. ACADIA Pharmaceuticals has a consensus target price of $25.25, suggesting a potential upside of 43.71%. Given Septerna's stronger consensus rating and higher probable upside, research analysts plainly believe Septerna is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00ACADIA Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.59 Do institutionals and insiders hold more shares of SEPN or ACAD? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is SEPN or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Septerna's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Septerna's return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A ACADIA Pharmaceuticals 13.83%25.83%14.71% SummaryACADIA Pharmaceuticals beats Septerna on 10 of the 13 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$749.92M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.9189.4217.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / BookN/A6.055.314.79Net IncomeN/A$154.90M$122.54M$225.00M7 Day Performance-0.41%1.35%1.42%2.37%1 Month Performance-30.44%0.41%2.50%4.40%1 Year PerformanceN/A3.08%25.29%20.10% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna1.6595 of 5 stars$16.89-0.5%$43.67+158.5%N/A$749.92MN/A0.00N/AACADACADIA Pharmaceuticals4.0907 of 5 stars$17.90+3.7%$25.25+41.1%-35.6%$2.98B$929.24M22.95510Short Interest ↑VCELVericel1.926 of 5 stars$59.62+0.2%$61.14+2.6%+48.9%$2.94B$226.84M993.83300XENEXenon Pharmaceuticals2.7564 of 5 stars$38.25-0.4%$56.00+46.4%-12.0%$2.92B$9.43M-13.56210Positive NewsMLTXMoonLake Immunotherapeutics1.9821 of 5 stars$45.26-2.3%$81.43+79.9%-18.2%$2.89BN/A-35.092Analyst UpgradeGap UpMORMorphoSys0.2266 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730DNLIDenali Therapeutics4.3872 of 5 stars$19.59+2.6%$38.91+98.6%+28.3%$2.82B$330.53M-7.10430Short Interest ↑MRUSMerus3.0447 of 5 stars$40.45-7.8%$85.64+111.7%+12.7%$2.77B$35.93M-10.2437High Trading VolumeZLABZai Lab2.7001 of 5 stars$25.21-0.4%$55.00+118.2%+11.1%$2.76B$355.75M-9.102,175SWTXSpringWorks Therapeutics1.5283 of 5 stars$37.01-13.9%$70.00+89.1%-13.1%$2.75B$135.49M-9.54230BHCBausch Health Companies3.3414 of 5 stars$7.40-6.1%$7.75+4.7%-8.8%$2.68B$9.47B-15.4220,270Short Interest ↓Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ACAD Competitors VCEL Competitors XENE Competitors MLTX Competitors MOR Competitors DNLI Competitors MRUS Competitors ZLAB Competitors SWTX Competitors BHC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEPN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
